MDT - Boston Scientific Has Become A Standout Growth Story In Med-Tech
2024-06-13 18:32:48 ET
Summary
- Boston Scientific Corporation is outperforming its peers in the med-tech sector with exceptional growth driven by key products like Farapulse and Watchman.
- Farapulse and Watchman are well-appreciated drivers with significant upside, but other contributors like urology, endoscopy, and peripheral interventions offer attractive complementary growth.
- Valuation is considerably more challenging today, and even my best-case valuation scenario doesn't suggest much upside from here.
It's one thing to stand out as an uncommonly good growth story when your peers aren't doing particularly well. It's quite another to be a standout growth story when your peers are doing well, but that's the case for Boston Scientific Corporation ( BSX ) today as key drivers like Farapulse pulsed field ablation (or PFA), Watchman , interventional cardiology, peripheral intervention, endoscopy, and urology are all pushing Boston Scientific to exceptional growth even at a time when its peers are logging high single-digit revenue growth....
Boston Scientific Has Become A Standout Growth Story In Med-Tech